Neuropace Inc
NPCE16.020USD
-0.170-1.05%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
533.16MMarket Cap
LossP/E TTM
More Details of Neuropace Inc Company
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Neuropace Inc Info
Ticker SymbolNPCE
Company nameNeuropace Inc
IPO dateApr 22, 2021
CEOBecker (Joel D)
Number of employees184
Security typeOrdinary Share
Fiscal year-endApr 22
Address455 N. Bernardo Avenue
CityMOUNTAIN VIEW
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94043
Phone16502372700
Websitehttps://www.neuropace.com/
Ticker SymbolNPCE
IPO dateApr 22, 2021
CEOBecker (Joel D)
Company Executives of Neuropace Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
591.92K
+0.41%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
64.90K
-2.02%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
38.48K
+3.03%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
17.10K
+9.68%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
13.23K
+9.92%
Mr. R. Scott (Scott) Huennekens
Mr. R. Scott (Scott) Huennekens
Independent Director
Independent Director
--
--
Ms. Renee Ryan
Ms. Renee Ryan
Independent Director
Independent Director
--
--
Mr. Joel D. Becker
Mr. Joel D. Becker
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa Andrade
Ms. Lisa Andrade
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Frank M. Fischer
Mr. Frank M. Fischer
Independent Chairman of the Board
Independent Chairman of the Board
591.92K
+0.41%
Dr. Martha J. Morrell, M.D.
Dr. Martha J. Morrell, M.D.
Chief Medical Officer
Chief Medical Officer
64.90K
-2.02%
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Chief Financial Officer
Chief Financial Officer
51.85K
--
Mr. Joseph S. (Joe) Lacob
Mr. Joseph S. (Joe) Lacob
Independent Director
Independent Director
38.48K
+3.03%
Ms. Rakhi Kumar, CPA
Ms. Rakhi Kumar, CPA
Independent Director
Independent Director
17.10K
+9.68%
Dr. Uri Geiger
Dr. Uri Geiger
Independent Director
Independent Director
13.23K
+9.92%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q1
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
23.52M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Accelmed Growth Partners Management Ltd
13.40%
Polar Capital LLP
9.36%
Soleus Capital Management, L.P.
8.94%
OrbiMed Advisors, LLC
7.90%
Morgan Stanley & Co. LLC
7.67%
Other
52.72%
Shareholders
Shareholders
Proportion
Accelmed Growth Partners Management Ltd
13.40%
Polar Capital LLP
9.36%
Soleus Capital Management, L.P.
8.94%
OrbiMed Advisors, LLC
7.90%
Morgan Stanley & Co. LLC
7.67%
Other
52.72%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
26.09%
Private Equity
21.30%
Hedge Fund
19.37%
Investment Advisor
17.07%
Research Firm
8.41%
Individual Investor
2.71%
Pension Fund
0.29%
Bank and Trust
0.08%
Venture Capital
0.03%
Other
4.66%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
198
31.14M
94.13%
-2.95M
2025Q2
184
29.13M
88.81%
-1.17M
2025Q1
183
29.76M
92.98%
+2.27M
2024Q4
144
26.53M
86.07%
-49.99K
2024Q3
134
26.01M
86.62%
-1.02M
2024Q2
129
25.88M
90.53%
+502.69K
2024Q1
131
24.82M
87.55%
-513.24K
2023Q4
113
24.06M
92.70%
-1.70M
2023Q3
103
24.86M
97.20%
-1.10M
2023Q2
106
24.30M
96.22%
-2.15M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Accelmed Growth Partners Management Ltd
4.43M
13.4%
--
--
Apr 09, 2025
Soleus Capital Management, L.P.
2.31M
6.99%
-295.21K
-11.32%
Jun 30, 2025
OrbiMed Advisors, LLC
2.61M
7.9%
-792.15K
-23.26%
Jun 30, 2025
Morgan Stanley & Co. LLC
2.58M
7.79%
+52.63K
+2.08%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.54M
4.64%
+803.81K
+109.91%
Jun 30, 2025
The Vanguard Group, Inc.
1.37M
4.14%
+171.20K
+14.29%
Jun 30, 2025
First Light Asset Management, LLC
1.38M
4.17%
-203.64K
-12.86%
Jun 30, 2025
Armistice Capital LLC
1.15M
3.48%
-1.28K
-0.11%
Jun 30, 2025
Kent Lake PR LLC
925.00K
2.8%
-25.00K
-2.63%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.64%
Principal U.S. Small-Cap ETF
0.05%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Proshares Ultra Russell 2000
0.01%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.64%
Principal U.S. Small-Cap ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Neuropace Inc?
The top five shareholders of Neuropace Inc are:
Accelmed Growth Partners Management Ltd holds 4.43M shares, accounting for 13.40% of the total shares.
Soleus Capital Management, L.P. holds 2.31M shares, accounting for 6.99% of the total shares.
OrbiMed Advisors, LLC holds 2.61M shares, accounting for 7.90% of the total shares.
Morgan Stanley & Co. LLC holds 2.58M shares, accounting for 7.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.54M shares, accounting for 4.64% of the total shares.
Accelmed Growth Partners Management Ltd holds 4.43M shares, accounting for 13.40% of the total shares.
Soleus Capital Management, L.P. holds 2.31M shares, accounting for 6.99% of the total shares.
OrbiMed Advisors, LLC holds 2.61M shares, accounting for 7.90% of the total shares.
Morgan Stanley & Co. LLC holds 2.58M shares, accounting for 7.79% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.54M shares, accounting for 4.64% of the total shares.
What are the top three shareholder types of Neuropace Inc?
The top three shareholder types of Neuropace Inc are:
Accelmed Growth Partners Management Ltd
Polar Capital LLP
Soleus Capital Management, L.P.
Accelmed Growth Partners Management Ltd
Polar Capital LLP
Soleus Capital Management, L.P.
How many institutions hold shares of Neuropace Inc (NPCE)?
As of 2025Q3, 198 institutions hold shares of Neuropace Inc, with a combined market value of approximately 31.14M, accounting for 94.13% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 5.32%.
What is the biggest source of revenue for Neuropace Inc?
In FY2025Q2, the -- business generated the highest revenue for Neuropace Inc, amounting to -- and accounting for --% of total revenue.
